QL-325 by QLSF Biotherapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QL-325 overview
QL-325 is under development for the treatment of acute myeloid leukemia (AML). It is a bi-specific monoclonal antibody which acts by targeting an undisclosed tumor-associated antigen and CD3.
For a complete picture of QL-325’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Source link
#QL325 #QLSF #Biotherapeutics #Acute #Myelocytic #Leukemia #AML #Acute #Myeloblastic #Leukemia #Likelihood #Approval